Perampanel: What is its Place in the Management of Partial Onset Epilepsy?

Neurology and Therapy

Volumn 2, Issue 1-2, 2013, Pages 13-24

  Ledingham, David R M ^a   Patsalos, Philip N ^b,c  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c EPILEPSY SOCIETY   (United Kingdom)

Author keywords

Adjunct therapy; AMPA receptor; First in class; Glutamate; Neurology; Non competitive AMPA receptor antagonist; Partial epilepsy; Perampanel; Refractory epilepsy

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CYTOCHROME P450 3A4; ESLICARBAZEPINE ACETATE; ETIRACETAM; GABAPENTIN; GLUTAMIC ACID; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXCARBAZEPINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AGGRESSION; BIOAVAILABILITY; DATA BASE; DEPOLARIZATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EPILEPTIC DISCHARGE; FOCAL EPILEPSY; HUMAN; LITERATURE; LONG TERM POTENTIATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NERVE CELL PLASTICITY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SIGNAL TRANSDUCTION; SOCIOECONOMICS;

EID: 84977090611     PISSN: 21938253     EISSN: 21936536     Source Type: Journal    
DOI: 10.1007/s40120-013-0012-3     Document Type: Review

References (52)

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342: 314-9.
2. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78: 1548-54.
3. Johannessen LC, Patsalos PN. Drug interactions involving the new second and third generation antiepileptic drugs. Expert Rev Neurother. 2010;10: 119-40.
4. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for the organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51: 676-85.
5. Banerjee PN, Filippi D, Hauser WA. The descriptive epidemiology of epilepsy-a review. Epilepsy Res. 2009;85: 31-45.
6. Guiliani G, Terziani S, Senigaglia AR, Luccioni G, Foschi N, Maffei C. Epilepsy in an Italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care. Acta Neurol Scand. 1992;85: 23-31.
7. Luengo A, Para J, Colas J, et al. Prevalence of epilepsy in northeast Madrid. J Neurol. 2001;248: 762-7.
8. Haerer AF, Anderson DW, Schoenberg BS. Prevalence and clinical features of epilepsy in a biracial United States population. Epilepsia. 1986;27: 66-75.
9. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia. 1991;32: 429-45.
10. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54: 551-63.
11. Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess. 2005;9: 1-157, iii-iv.
12. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;24;369: 1000-15.
13. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51: 1069-77.
14. Michael B, Marson AG. Clobazam as an add-on in the management of refractory epilepsy. Cochrane Database Syst Rev. 2008;2: CD004154.
15. Chang X, Yuan H, Wang Y, Xu H, Zheng R. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2011;12: CD008907.
16. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. Gabapentin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2000;3: CD001415.
17. Ramaratnam S, Marson AG, Baker GA. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2001;3: CD001909.
18. Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev. 2012;9: CD001901.
19. Castillo S, Schmidt DB, White S. Oxcarbazepine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2000;3: CD002028.
20. Pulman J, Marson AG, Hutton JL. Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2012;5: CD001908.
21. Jette N, Hemming K, Hutton JL, Marson AG. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2008;3: CD001417.
22. Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev. 2013;1: CD007302.
23. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2005;4: CD001416.
24. Schmidt D. Efficacy of new antiepileptic drugs. Epilepsy Curr. 2011;11: 9-11.
25. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia. 2010;51: 7-26.
26. Tellez-Zenteno JF, Dhar R, Wiebe S. Long-term seizure outcomes following epilepsy surgery: a systematic review and meta-analysis. Brain. 2005;128: 1188-98.
27. Besag FM, Patsalos PN. New developments in the treatment of partial-onset epilepsy. Neuropsychiatr Dis Treat. 2012;8: 455-64.
28. 3H]batrachotoxinin A 20-α-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol. 1982;22: 627-35.
29. Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther. 1993;266: 829-35.
30. Sveinbjornsdottir S, Sander JW, Upton D, et al. The excitatory amino acid antagonist S-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 1993;16: 165-74.
31. Yamaguchi S, Donevan SD, Rogawaski MA. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 1993;15: 179-84.
32. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52: 1331-40.
33. Traus RD, Miles R, Jeffreys JG. Synaptic and intrinsic conductances shape picrotoxin-induced synchronized after discharges in the guinea-pig hippocampal slice. J Physiol. 1993;461: 525-47.
34. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11: 56-63.
35. Collingridge GL, Isaac JT, Wang YT. Receptor trafficking and synaptic plasticity. Nat Rev Neurosci. 2004;5: 952-62.
36. Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomised dose-escalation studies. Acta Neurol Scand. 2012;125: 8-15.
37. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79: 589-96.
38. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54: 117-25.
39. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78: 1408-15.
40. Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand. 2012;126: 263-9.
41. Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, open-label extension study 307. Epilepsia. 2013;54: 126-34.
42. Serratosa JM, Villanueva V, Kerling F, Kasper BS. Safety and tolerability of perampanel: a review of clinical trial data. Acta Neurol Scand. 2013;127: 30-5.
43. Perampanel (Fycompa). Summary of Product Characteristics. 2012. Eisai Europe Ltd. Available at: http://www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/WC500130815. pdf. Accessed July 31, 2013.
44. Plosker GL. Perampanel: as adjunctive therapy in patients with partial-onset seizures. CNS Drugs. 2012;26: 1085-96.
45. Committee for Medicinal Products for Human Use. Fycompa (perampanel) assessment report. European Medicines Agency 424476, 2012. Available at: http://www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002434/WC500130839. pdf. Accessed July 31, 2013.
46. Kamiński RM, van Rijn CM, Turski WA, Czuczwar SJ, van Luijtelaar G. AMPA and GABA(B) receptor antagonists and their interaction in rats with a genetic form of absence epilepsy. Eur J Pharmacol. 2001;430: 251-9.
47. Ko D, Ramsay RE. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalised convulsive seizures. Acta Neurol Scand. 2013;127: 36-43.
48. Ramsay RE, Detoledo J. Tonic-clonic seizures: a systematic review of antiepilepsy drug efficacy and safety. Clin Ther. 1997;19: 433-46.
49. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures a randomised controlled trial. Epilepsia. 2010;51: 958-67.
50. Schapel GJ, Beran RG, Vajda FJ, et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry. 1993;56: 448-53.
51. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicentre double-blind, randomized placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia. 2000;41: 1179-86.
52. Ben-Menachem E, Henrikson O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 1996;37: 539-43.